• 1. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 2. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 3. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 4. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 5. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549

Introduction to 3-(4-bromophenyl)cyclobutan-1-amine (CAS No. 1156296-38-6)

3-(4-bromophenyl)cyclobutan-1-amine, identified by the Chemical Abstracts Service Number (CAS No.) 1156296-38-6, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This bicyclic amine derivative features a cyclobutane ring substituted with a brominated phenyl group, making it a versatile scaffold for the development of novel bioactive molecules. The structural motif of this compound has garnered attention due to its potential applications in drug discovery, particularly in the synthesis of pharmacophores targeting various biological pathways.

The bromophenyl moiety in 3-(4-bromophenyl)cyclobutan-1-amine plays a crucial role in modulating the electronic and steric properties of the molecule. The presence of the bromine atom at the para position relative to the amine group enhances reactivity, allowing for further functionalization through cross-coupling reactions such as Suzuki-Miyaura or Buchwald-Hartwig couplings. These transformations are pivotal in constructing more complex molecular architectures, which can be essential for achieving high affinity and selectivity in drug design.

Recent advancements in medicinal chemistry have highlighted the utility of cyclobutane derivatives in medicinal applications. The rigid three-membered ring in 3-(4-bromophenyl)cyclobutan-1-amine contributes to optimal spatial orientation of substituents, which is critical for binding to biological targets such as enzymes and receptors. This structural feature has been leveraged in the design of inhibitors targeting kinases and other enzyme families implicated in diseases ranging from cancer to inflammatory disorders.

In the context of drug discovery, 3-(4-bromophenyl)cyclobutan-1-amine serves as a valuable intermediate for synthesizing analogs with tailored pharmacological properties. Researchers have demonstrated its incorporation into libraries of small molecules for high-throughput screening (HTS) campaigns, aiming to identify lead compounds with therapeutic potential. The bromine substituent further facilitates derivatization, enabling the exploration of diverse chemical space without compromising structural integrity.

The pharmacological profile of 3-(4-bromophenyl)cyclobutan-1-amine and its derivatives has been explored in several preclinical studies. Notably, compounds derived from this scaffold have shown promise as inhibitors of cyclin-dependent kinases (CDKs), which are key regulators of cell cycle progression. By modulating CDK activity, these molecules may offer therapeutic benefits in oncology, particularly against cancers with aberrant cell cycle control. Additionally, preliminary data suggest potential interactions with other targets such as protein tyrosine kinases (PTKs), underscoring its broad applicability.

The synthesis of 3-(4-bromophenyl)cyclobutan-1-amine involves multi-step organic transformations that highlight modern synthetic methodologies. Key steps include bromination of a phenyl precursor followed by cycloaddition reactions to construct the cyclobutane core. Advances in catalytic systems have enabled more efficient and sustainable routes to this intermediate, aligning with green chemistry principles. Such improvements are essential for large-scale production and commercialization of pharmaceuticals derived from this compound.

From a computational chemistry perspective, 3-(4-bromophenyl)cyclobutan-1-amine has been subjected to extensive molecular modeling studies to elucidate its binding interactions with biological targets. Quantum mechanical calculations have provided insights into its electronic structure and reactivity, aiding rational drug design efforts. These computational approaches are increasingly integral to modern medicinal chemistry workflows, complementing experimental techniques and accelerating the discovery process.

The role of 3-(4-bromophenyl)cyclobutan-1-amine extends beyond academic research into industrial applications. Pharmaceutical companies have incorporated this compound into their proprietary libraries, recognizing its synthetic versatility and potential therapeutic relevance. As drug development pipelines continue to evolve, intermediates like 3-(4-bromophenyl)cyclobutan-1-amine will remain indispensable tools for chemists seeking innovative solutions to unmet medical needs.

In conclusion, 3-(4-bromophenyl)cyclobutan-1-amine (CAS No. 1156296-38-6) represents a compelling example of how structural innovation can drive pharmaceutical progress. Its unique combination of reactivity and binding properties makes it a cornerstone in the synthesis of bioactive molecules targeting diverse diseases. As research continues to uncover new applications for this compound and its derivatives, it will undoubtedly remain a focal point in both academic and industrial settings within the pharmaceutical industry.

• 1895751-01-5(1-[1-(4-Bromophenyl)cyclobutyl]-3-methylbutylamine)
• 1311316-19-4(3-(4-Bromophenyl)cyclobutan-1-amine hydrochloride)
• 1388095-52-0((1S,3R)-3-(4-Bromophenyl)cyclopentanamine)
• 1267918-24-0(2-(4-BROMOPHENYL)CYCLOHEXANAMINE)
• 1807896-07-6(trans-3-(4-bromophenyl)cyclobutanamine;hydrochloride)
• 1094218-30-0(1-(4-bromophenyl)cyclobutan-1-amine)
• 1951439-61-4(1-(4-Bromophenyl)cyclobutan-1-amine hydrobromide)
• 1390706-66-7((1R,3S)-3-(4-Bromophenyl)cyclopentanamine)
• 1156295-97-4(3-(3-Bromophenyl)cyclobutan-1-amine)
• 1807937-14-9(trans-3-(4-bromophenyl)cyclobutanamine)